Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT06686771 by Canadian Cancer Trials Group, with a registry enrolment figure of 320 participants, started 2025-12-16 and due to reach its primary completion in 2030-02-28. Interventions recorded: SBRT; First or second-line standard of care therapy. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Progression-free survival; Overall survival. Lung eligibility wording from the registry: "* Metastatic disease (stage IV) detected on imaging and histologically and/or cytologically confirmed NSCLC as per the WHO Classification of Tumors and AJCC 8th Edition TNM Classification, without a driver mutation with an actionable first-line targeted therapy, for whom either ICI alone or combinat". Sites: Canada, United States. No results are recorded here; the registry entry is the source.